Indian equity markets showed recovery with a rise in NSE Nifty 50, ending a four-session losing streak. Several companies reported their Se...

Private equity firms, including 360 ONE and TR Capital, are negotiating to acquire a stake in Hector Beverages. Existing investors, such as...

India's pharmaceutical companies are expected to have a mixed performance in the upcoming September quarter. Companies like Sun Pharmaceuti...

At least 46 companies are expected to report double-digit profit declines in Q2, despite Motilal Oswal projecting 22% earnings growth for i...

At CPHI Milan, Indian pharma players are looking beyond traditional exports, using partnerships, licensing, CDMO, and differentiated produc...

Revenue and net profit of Nifty 50 companies are projected to grow by nearly 20% year-on-year. Analysts note that performance is driven by ...

The Delhi High Court ordered the removal of Razenta Pharmaceuticals' Daplogin trademark. This decision came as the mark was deemed deceptiv...

Indian pharmaceutical firms experienced a challenging June quarter, marked by declining US business profits. Dr Reddy's and Cipla saw signi...

Cipla reported a 39% drop in net profit to ₹789 crore for the June quarter due to weakness in its North America business and margin compres...

Cipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...

Cipla shares dropped 5% after reporting a 57% year-on-year decline in net profit to Rs 676 crore, impacted by a fall in gRevlimid sales. Re...

Cipla's Q3FY25 revenue is expected to grow 3.1-7%, with profit estimates ranging from a 2.2% decline to 14% growth. Brokerages have differi...

Drug maker Cipla reported a 33% year-on-year (YoY) jump in net profit to Rs 1049 crore in Q3FY24, led by strong US and India sales momentum.

The bottomline was higher than the Rs 1,006 crore which was expected by analysts in an ET Now poll. Cipla's consolidated margin came in at ...

Cipla's total revenue from operations rose to Rs 5,038.29 crore, up 14.62 per cent from Rs 4,395.78 crore a year ago.

Kotak Institutional Equities expects Cipla to report a 14.1 per cent rise in net profit, while net sales may have increased 6 per cent from...

Leading generic drug maker Cipla today said that it expects 20 per cent growth in revenues in the current fiscal (FY 16).